Figure 14-2. Disparities Table for Focus Area 14: Immunization and Infectious Diseases

Midcourse Review > Table of Contents > Focus Area 14: Immunization and Infectious Diseases > Disparities Table

Disparities from the best group rate for each characteristic at the most recent data point and changes in disparity from the baseline to the most recent data point.

Race and Ethnicity | Gender and Education | Income, Location, and Disability

Characteristics: Income, Location, and Disability
Population-based objectives	Poor	Near poor	Middle/high income	Summary index	Urban or metropolitan	Rural or non-metropolitan	Persons with disabilities	Persons without disabilities
14-3a. Hepatitis B: 19-24 years (1997, 2003)
14-3b. Hepatitis B: 25-39 years (1997, 2003)
14-3c. Hepatitis B: 40+ years (1997, 2003)
14-4. Bacterial meningitis: 1-23 months (1998, 2003)
14-5a. Invasive pneumococcal infections: < 5 years (1997, 2002)
14-5b. Invasive pneumococcal infections: 65+ years (1997, 2002)
14-5c. Invasive penicillin-resistant pneumococcal infections: < 5 years (1997, 2002)
14-5d. Invasive penicillin-resistant pneumococcal infections: 65+ years (1997, 2002)
14-6. Hepatitis A (1997, 2003)
14-7. Meningococcal disease (1997, 2002)
14-8. Lyme disease (1992-96, 2002)
14-9. Hepatitis C (1997, 2003)
14-11. Tuberculosis (1998, 2003)
14-12. Curative therapy for tuberculosis (1996, 2000)
14-16. Invasive early onset group B streptococcal disease (1996, 2002)
14-17. Peptic ulcer hospitalizations (1998, 2001)
14-18. Antibiotics prescribed for ear infections: < 5 years (1996-97, 2002-03)
14-19. Antibiotics prescribed for the common cold (1996-97, 2002-03)
14-22a. DTaP immunization: 4 doses, 19-35 months (1998, 2003)
14-22b. Haemophilus influenzae type B immunization: 3 doses, 19-35 months (1998, 2003)
14-22c. Hepatitis B immunization: 3 doses, 19-35 months (1998, 2003)
14-22d. MMR immunization: 1 dose, 19-35 months (1998, 2003)
14-22e. Polio immunization: 3 doses, 19-35 months (1998, 2003)
14-22f. Varicella immunization: 1 dose, 19-35 months (1998, 2003)
14-22g. PCV immunization: 4 doses, 19-35 months (2002, 2003)
14-24a. Fully immunized children: 19-35 months (1998, 2002)
14-27a. Hepatitis B immunization: 3+ doses, 13-15 years (1997, 2003)
14-27b. MMR immunization: 2+ doses, 13-15 years (1997, 2003)
14-27c. Tetanus-diphtheria booster: 1+ dose(s), 13-15 years (1997, 2003)
14-27d. Varicella immunization: 1+ dose(s), 13-15 years (1997, 2003)
14-29a. Influenza vaccination in past year: noninstitutionalized, 65+ years (1998, 2003)
14-29b. Pneumococcal vaccination ever received: noninstitutionalized, 65+ years (1998, 2003)
14-29c. Influenza vaccination in past year: noninstitutionalized high-risk, 18-64 years (1998, 2003)
14-29d. Pneumococcal vaccination ever received: noninstitutionalized high-risk, 18-64 years (1998, 2003)
14-29e. Influenza vaccination in past year: institutionalized, 18+ years (1997, 1999)
14-29f. Pneumococcal vaccination ever received: institutionalized, 18+ years (1997, 1999)
14-29g. Influenza vaccination in past 12 months: health care workers, 18-64 years (2000)

Notes:

Data for objectives 14-1a through k, 14-2, 14-3d through g, 14-10, 14-13, 14-14, 14-20a through e, 14-21, 14-22h, 14-23a through k, 14-24b, 14-25a and b, 14-26, 14-28a, b, and c, 14-30a and b, and 14-31a and b are unavailable or not applicable. Objective 14-15 was deleted at the midcourse.

Years in parentheses represent the baseline data year and the most recent data year (if available).

Disparity from the best group rate is defined as the percent difference between the best group rate and each of the other group rates for a characteristic (for example, race and ethnicity). The summary index is the average of these percent differences for a characteristic. Change in disparity is estimated by subtracting the disparity at baseline from the disparity at the most recent data point. Change in the summary index is estimated by subtracting the summary index at baseline from the summary index at the most recent data point. See Technical Appendix for more information.

The best group rate at the most recent data point.

The group with
the best rate
for specified characteristic.

Most favorable group rate for specified characteristic, but reliability criterion not met.

Best group rate reliability criterion not met.

Percent difference from the best group rate

Disparity from the best group rate at the most recent data point.

Less than 10 percent or not statistically significant

10-49 percent

50-99 percent

100 percent or more

Increase in disparity (percentage points)

Changes in disparity over time are shown when the change is greater than or equal to 10 percentage points and statistically significant, or when the change is greater than or equal to 10 percentage points and estimates of variability were not available.

10-49

50-99

100 or more

Decrease in disparity (percentage points)

10-49

50-99

100 or more

Availability of data.

Data not available.

Characteristic not selected for this objective.

^* The variability of best group rates was assessed, and disparities of ≥ 10% are statistically significant at the 0.05 level. Changes in disparity over time, noted with arrows, are statistically significant at the 0.05 level. See Technical Appendix.
^† Measures of variability were not available. Thus, the variability of best group rates was not assessed, and the statistical significance of disparities and changes in disparity over time could not be tested. See Technical Appendix.
¹Data are for Asians or Pacific Islanders.
² Data include persons of Hispanic origin.
³ Disparity declined substantially for American Indians or Alaska Natives relative to Asians or Pacific Islanders, the group with the best rate at baseline.
⁴ Baseline data by race and ethnicity are for 2000.
⁵ Baseline data by race and ethnicity are for 2001.
⁶ Baseline data only.
⁷ Baseline data by race and ethnicity are for 1999.

<< Previous—Disparities Table: Gender and Education | Table of Contents | Next—Objectives and Subobjectives >>

[ Top ]